China SXT Pharmaceuticals, Inc. SXTC
Last close
—
Market cap
—
52-week range
— - —
No price or market cap here: this company files no 10-K, so the only share count SEC publishes for it counts its ordinary shares in its home market, while its US listing is a depositary receipt standing for some number of them. That number is in no filing, so a price multiplied by that count is not this company's value and is not shown. The financial statements below are as filed.
Valuation FY2025 figures against the last close
P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-9.13
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.1M | $1.7M | $1.9M | $2.0M | $2.6M | $4.8M | $5.2M | $7.0M | $7.0M | $4.9M |
| Cost of revenue | $889.4K | $1.4M | $1.4M | $1.5M | $1.4M | $1.9M | $2.5M | $2.4M | $3.6M | $2.6M |
| Gross profit | $248.7K | $367.4K | $554.0K | $426.3K | $1.3M | $2.8M | $2.7M | $4.6M | $3.4M | $2.3M |
| R&D | — | — | $184.2K | $200.7K | $367.0K | — | — | — | — | — |
| SG&A | $7.1M | $2.8M | $2.6M | $5.6M | $5.5M | $3.4M | $2.5M | $1.2M | $1.3M | $565.5K |
| Total operating expenses | $7.4M | $3.0M | $3.1M | $6.0M | $6.4M | $5.0M | $4.0M | $2.8M | $1.8M | $709.8K |
| Operating income | -$7.1M | -$2.7M | -$2.5M | -$5.6M | -$5.2M | -$2.2M | -$1.3M | $1.8M | $1.6M | $1.6M |
| Interest expense | $63.0K | $648.2K | $544.3K | $476.8K | $36.7K | $1.6M | $3.3M | $5.2K | $779 | $40.4K |
| Pre-tax income | -$6.2M | -$3.3M | -$3.1M | -$5.9M | -$5.4M | -$2.9M | -$10.4M | $1.8M | $1.6M | $1.6M |
| Income tax | — | — | — | — | $328.1K | $192.7K | $101.7K | $252.2K | $440.1K | $395.0K |
| Net income | -$6.2M | -$3.3M | -$3.1M | -$5.9M | -$5.7M | -$2.7M | -$10.3M | $1.5M | $1.2M | $1.2M |
| EPS, basic | -9.13 | -348.17 | -4,285.66 | -177.84 | -137.92 | -3.82 | 33.28 | 0.07 | 0.06 | 0.06 |
| EPS, diluted | -9.13 | -348.17 | -4,285.66 | -177.84 | -137.92 | -3.82 | 1.66 | -0.30 | 0.06 | 0.06 |
| Shares, diluted (wtd. avg.) | 679,648 | 9,489 | 723 | 33,372 | 41,591 | 719,549 | 309,108 | 20.6M | 20.0M | 20.0M |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $28.2M | $18.1M | $12.1M | $17.4M | $15.6M | $13.4M | $7.3M | $9.3M | $657.8K | $65.6K |
| Receivables | $931.6K | $1.3M | $1.3M | $1.3M | $3.3M | $4.5M | $3.8M | $4.2M | $2.6M | — |
| Inventory | $777.1K | $828.1K | $794.9K | $531.3K | $1.0M | $859.7K | $892.8K | $1.0M | $1.3M | — |
| Total current assets | $34.5M | $21.3M | $14.2M | $19.5M | $22.5M | $23.2M | $19.6M | $15.6M | $6.1M | — |
| Property, plant and equipment | $117.1K | $178.6K | $328.8K | $962.2K | $1.2M | $1.4M | $1.6M | $1.2M | $862.5K | — |
| Other intangibles | $6.3K | $11.8K | $19.1K | $27.9K | $38.8K | $45.8K | $50.1K | $61.1K | $60.7K | — |
| Total assets | $34.8M | $21.7M | $23.1M | $29.6M | $33.5M | $34.5M | $21.7M | $17.5M | $7.7M | — |
| Accounts payable | $497.6K | $1.2M | $1.3M | $1.4M | $1.5M | $1.5M | $1.9M | $1.7M | $2.4M | — |
| Short-term debt | $355.2K | $8.8K | $21.3K | $7.9K | $11.4K | $37.1K | $43.9K | $27.8K | — | — |
| Total current liabilities | $4.3M | $6.0M | $8.9M | $14.5M | $17.1M | $18.6M | $12.3M | $6.3M | $4.4M | — |
| Long-term debt | $644.4K | $96.3K | $117.1K | $117.9K | — | $6.3K | $36.5K | $41.7K | — | — |
| Total liabilities | $5.0M | $6.2M | $9.2M | $14.9M | $17.1M | $18.6M | $12.3M | $6.4M | $4.4M | — |
| Retained earnings | -$34.2M | -$28.0M | -$24.7M | -$21.6M | -$15.7M | -$10.0M | -$7.2M | $3.1M | $1.5M | — |
| Total equity | $29.7M | $15.4M | $13.9M | $14.7M | $16.1M | $16.0M | $9.4M | $11.1M | $3.3M | $1.9M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$4.0M | -$2.3M | -$1.9M | -$80.8K | $268.3K | -$1.3M | $934.2K | $239.2K | $1.9M | $293.0K |
| Depreciation and amortisation | $73.7K | $82.3K | $203.2K | $250.2K | $320.0K | $345.4K | $331.8K | $180.9K | $129.4K | $94.4K |
| Stock-based compensation | $5.3M | — | $352.1K | $554.6K | $2.3M | — | — | — | — | — |
| Capital expenditure | — | $2.0K | $7.1K | — | — | — | $130.8K | $535.8K | $436.0K | $179.2K |
| Investing cash flow | -$1.3M | $63.5K | $26.4K | -$12.3K | -$46.9K | -$5.8M | -$5.5M | -$610.1K | -$1.1M | -$186.3K |
| Financing cash flow | $14.4M | $8.4M | -$2.6M | $2.9M | $1.6M | $12.4M | $3.0M | $9.0M | -$314.2K | -$50.6K |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001213900-26-074310.
Plot the figures US dollars
Income statement
Revenue
Cost of revenue
Gross profit
R&D
SG&A
Total operating expenses
Operating income
Interest expense
Pre-tax income
Income tax
Net income
EPS, basic
EPS, diluted
Shares, diluted (wtd. avg.)
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.9M | $7.0M | $7.0M | $5.2M | $4.8M | $2.6M | $2.0M | $1.9M | $1.7M | $1.1M |
| Gross profit | $2.3M | $3.4M | $4.6M | $2.7M | $2.8M | $1.3M | $426.3K | $554.0K | $367.4K | $248.7K |
| Net income | $1.2M | $1.2M | $1.5M | -$10.3M | -$2.7M | -$5.7M | -$5.9M | -$3.1M | -$3.3M | -$6.2M |
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |